Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Is Diabetes Mellitus a Prognostic Factor for Survival in Patients with Small Cell Lung Cancer?

  • Published : 2012.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Previous studies have pointed to many different prognostic factors for small cell lung cancer (SCLC) but diabetes mellitus (DM) has not been clearly or consistently identified as of prognostic value. The aim of this study was to investigate the prognostic significance of the characteristics of patients and clinical laboratory tests in SCLC. Specifically, we investigated that the impact of DM for survival in the patients receiving first-line etoposide plus cisplatin (EP) chemotherapy. Methods: We retrospectively reviewed 161 patients with SCLC with a focus on DM and other potential prognostic variables were chosen for univariate and multivariate analyses with respect to survival. Result: Among the sixteen variables of univariate analysis, five were identified to have prognostic significance: performance status (PS) (p<0.001), stage (p=0.001), DM (p=0.005), serum albumin (p<0.001) and hemoglobin levels (p=0.03). Multivariate analysis showed PS, stage and serum albumin level to be independent prognostic factors for survival (p=0.02, p=0.02 and p=0.009 respectively), but DM was not an independnet factor. Conclusion: In conclusion, PS, stage and serum albumin level were identified as important prognostic factors, while DM at the time of diagnosis of SCLC did not have prognostic importance for survival.

Keywords

References

  1. Albain KS, Crowley JJ, LeBlanc M, Livingston RB (1990). Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol, 8, 1563-74.
  2. Barone BB, Yeh HC, Snyder CF, et al (2004). Long-term allcause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA, 17, 2754-64.
  3. Boyle P, Ferlay J (2005). Cancer incidence and mortality in Europe, 2004. Ann Oncol, 16, 481-8. https://doi.org/10.1093/annonc/mdi098
  4. Bremnes RM, Sundstrom S, Aasebo U, et al (2003). Norweigian Lung Cancer Study Group. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer, 39, 303-13. https://doi.org/10.1016/S0169-5002(02)00508-1
  5. Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N (1987). Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer,151, 46-9.
  6. Fry WA, Menck HR, Winchester DP (1996). The National Cancer Data Base report on lung cancer. Cancer, 77, 1947-55. https://doi.org/10.1002/(SICI)1097-0142(19960501)77:9<1947::AID-CNCR27>3.0.CO;2-Z
  7. Foster NR, Mandrekar SJ, Schild SE, et al (2009). Prognostic Factors Differ by Tumor Stage for Small Cell Lung Cancer. Cancer, 15, 2721-31.
  8. Hansen O, Sørensen P, Hansen KH (2010). The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period. Lung Cancer, 68, 111-4. https://doi.org/10.1016/j.lungcan.2009.05.015
  9. Huang YC, Lin JK, Chen WS, et al (2011). Diabetes mellitus negatively impacts survival of patients with colon cancer, particularly in stage II disease. J Cancer Res Clin Oncol, 137, 211-20. https://doi.org/10.1007/s00432-010-0879-7
  10. Jackman DM, Johnson BE (2005). Small-cell lung cancer. Lancet, 366, 1385-96. https://doi.org/10.1016/S0140-6736(05)67569-1
  11. Krishnan S, Rana V, Janjan NA, et al (2006). Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer, 107, 2589-96. https://doi.org/10.1002/cncr.22328
  12. Lassen U, Osterlind K, Hansen M, et al (1995). Longterm survival in small-cell lung cancer: post-treatment characteristics in patients surviving 5 to ${\geq}$ 18 years-an analysis of 1,714 consecutive patients. J Clin Oncol, 13, 1215-20.
  13. Mitry E, Douillard JY, Van Cutsem E, et al (2004). Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trial. Ann Oncol, 15, 1013-7. https://doi.org/10.1093/annonc/mdh267
  14. Quoix E, Purohit A, Faller-Beau M, et al (2000). Comparative prognostic value of lactate dehydrogenase and neuronspecific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer, 30, 127-34. https://doi.org/10.1016/S0169-5002(00)00131-8
  15. Park SM, Lim MK, Shin SA, Yun YH (2006). Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study. J Clin Oncol, 24, 5017-24. https://doi.org/10.1200/JCO.2006.07.0243
  16. Peairs KS, Barone BB, Snyder CF, et al (2011). Diabetes mellitus and breast cancer outcomes: a systematic review and metaanalysis. J Clin Oncol, 29, 40-6. https://doi.org/10.1200/JCO.2009.27.3011
  17. Pelayo Alvarez M, Gallego Rubio O, Bonfill Cosp X, Agra Varela Y (2009). Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev: CD001990.
  18. Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P (2008). The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM Classification of Malignant Tumors and the proposals for the 7th edition. J Thorac Oncol, 3, 457-66. https://doi.org/10.1097/JTO.0b013e31816de2b8
  19. Serke M, Schonfeld N (2007). Diagnosis and staging of lung cancer. Dtsch Med Wochenschr, 132, 1165-9. https://doi.org/10.1055/s-2007-979393
  20. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P (2003). Impact of comorbidity on lung cancer survival. Int J Cancer, 103, 792-802. https://doi.org/10.1002/ijc.10882
  21. Tas F, Aydiner A, Demir C, Topuz E (2001). Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer. Am J Clin Oncol, 24, 376-8. https://doi.org/10.1097/00000421-200108000-00013
  22. Van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, et al (2007). Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer, 120, 1986-92. https://doi.org/10.1002/ijc.22532
  23. Varlotto J, Medford-Davis LN, Recht A, et al (2011). Confirmation of the role of diabetes in the local recurrence of surgically resected non-small cell lung cancer. Lung Cancer, 75, 381-90.
  24. Win T, Sharples L, Groves AM, et al (2008). Predicting survival in potentially curable lung cancer patients. Lung, 186, 97-102. https://doi.org/10.1007/s00408-007-9067-1
  25. Yip D, Harper PG (2000). Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer, 28, 173-85. https://doi.org/10.1016/S0169-5002(00)00105-7
  26. Zelen M (1973). Keynote address on biostatistics and data retrieval. Cancer Chemother Rep, 4, 31-42.

Cited by

  1. Diabetes - Increased Risk for Cancers through Chromosomal Aberrations? vol.15, pp.11, 2014, https://doi.org/10.7314/APJCP.2014.15.11.4571
  2. Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer vol.15, pp.1, 2015, https://doi.org/10.1186/s12885-015-2012-4